To check the safety of Test Products by 24 Hours Patch Test on Adult Healthy Human Subjects.
- Conditions
- Adequate representation of varied skin types.
- Registration Number
- CTRI/2023/06/053467
- Lead Sponsor
- TTK Healthcare Ltd Protective Devices Division
- Brief Summary
This is a Single-center, Evaluator blinded study in healthy adult human subjects.
Single 24-hour application of sponsor(s) provided test products along with positive and negative control will be kept in contact with subjects’ skin under occlusion| semi-occlusion patch for at least 24 hr. 26 subjects of varied skin types (Oily, Dry, Normal, and Combination preferably equal ratio will be enrolled into the study to get 24 completed subjects at the end of study
There are three visits in this study and one optional visit. Pre-Screening: Lactic Acid Stinging Test and Modified Dr Baumann’s kin type questionnaries
Visit 1 (Day 01): Screening Enrollment and patch Application
Visit 2 (Day 02): Patch Removal after 24 hours of patch application & 30+5 min Irritation scoring upon patch removal
Visit 3(Day 03): 24 ±2 hours Irritation scoring after path removal
Visit 4 (Day 09): Subject will be contact telephonically on Day 8 for any sign of irritation at the patch application site. follow-up visit for reactions if any to confirm recovery(optional, if deemed necessary) [irritation scoring at 168+2 hours post-patch removal
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 26
- Age: 18-65 years (both inclusive) at the time of consent.
- Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- colour determinationbr/> scale).
- Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application.
- Subject who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results.
- The subject is in good general health as determined by the Investigator on the basis of medical history.
- Subjects are willing to maintain the test patchesin designated positions for 24 Hours.
- Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
- Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instructions given.
- Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.
- Medication which may affect skin response and/or past medical history.
- Subject having history of diabetes 4.
- Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
- Subject suffering from any active clinically significant skin diseases which may contraindicate.
- Participation in any patch test for irritation or sensitization within the last four weeks.
- Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).
- Use of any: i.
- Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.
- Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application.
- Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted) 10.
- Topical drugs used at application site.
- Subject with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous.
- Individual who has a medical condition or is taking or has taken a medication which, in the Investigator’s judgment, makes the subject ineligible or places the subject at undue risk.
- Subject with known allergy or sensitization to medical adhesives, bandages.
- Participation in other patch study simultaneously.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the dermatological safety of the test 30 mins, 24 Hour & 168 hour (if needed). products by 24 Hours Patch Test Under 30 mins, 24 Hour & 168 hour (if needed). 30 mins, 24 Hour & 168 hour if needed. 30 mins, 24 Hour & 168 hour (if needed). Complete Occlusion on healthy adult human 30 mins, 24 Hour & 168 hour (if needed). subjects & adequate representation of varied 30 mins, 24 Hour & 168 hour (if needed). skin types (Oily, Dry, Normal and Combination) 30 mins, 24 Hour & 168 hour (if needed).
- Secondary Outcome Measures
Name Time Method Safety of Skin 30 mins, 24 Hour & 168 hour (if needed).
Trial Locations
- Locations (1)
NovoBliss Research Pvt. Limited
🇮🇳Gandhinagar, GUJARAT, India
NovoBliss Research Pvt. Limited🇮🇳Gandhinagar, GUJARAT, IndiaDr Nayan PatelPrincipal investigator9909013286dr.nayan@novobliss.in